@article{48988a651a454f0fba052c902ab954d5,
title = "Stopping immunomodulatory medications in MS: Frequency, reasons and consequences",
abstract = "Prolonged periods of disease quiescence during long term treatment of patients with clinically isolated syndrome and MS may prompt consideration of discontinuing disease-modifying therapy (DMT). We reviewed pertinent studies to identify the frequency and reasons for discontinuation of DMT.",
keywords = "Disease activity, Multiple sclerosis, Treatment discontinuation",
author = "Tobin, {W. O.} and Weinshenker, {B. G.}",
note = "Funding Information: Dr. Weinshenker serves on data safety monitoring boards for Novartis, Biogen Idec and Mitsubishi. He serves on adjudication panel for MedImmune. He has received payment for consultation from Novartis, Elan, GlaxoSmithKline, Ono, CHORD, Chugai, and Asahi Kasei Medical Company. He serves on the editorial boards of Neurology, the Canadian Journal of Neurological Sciences, and the Turkish Journal of Neurology. He has received research support from the Guthy-Jackson Charitable Foundation . He receives license royalties from RSR Ltd. and Oxford University for a patent regarding AQP4-associated antibodies for diagnosis of neuromyelitis optica. Publisher Copyright: {\textcopyright} 2015 Elsevier B.V. All rights reserved. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2015",
month = sep,
day = "1",
doi = "10.1016/j.msard.2015.07.004",
language = "English (US)",
volume = "4",
pages = "437--443",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "5",
}